Core Insights - SS Innovations International, Inc. has successfully completed the world's first robotic telesurgery for weight loss using the SSi Mantra 3 surgical robotic system, marking a significant advancement in robotic surgery technology [1][4] Company Overview - SS Innovations is dedicated to making robotic surgery affordable and accessible globally, with a focus on innovative surgical robotic technologies [5] - The company is headquartered in India and aims to expand its global presence with user-friendly and cost-effective surgical robotic solutions [5] Technological Achievement - The robotic telesurgery bridged a distance of 560 miles between Gurugram and Indore, India, performed with zero perceptible lag and flawless precision [2][7] - The procedures involved two One-Anastomosis Gastric Bypass (OAGB) surgeries, showcasing the capabilities of the SSi Mantra 3 system [3][7] Leadership Commentary - Dr. Sudhir Srivastava, CEO, emphasized that this achievement bridges healthcare gaps and makes advanced surgical expertise accessible to remote regions [4] - Dr. Mohit Bhandari, who led the surgery, highlighted the potential of robotic telesurgery to redefine surgical care and improve access to healthcare [4] Future Vision - SS Innovations aims to continue refining its technology to enhance surgical efficiency and improve patient outcomes, particularly in underserved areas [4]

CAESAREA, Israel, July 10, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it has commenced its previously disclosed rights offering (the "Rights Offering").Pursuant to the Rights Offering, the Company is distributing to all holders of record of the Company's ordinary shares, no par value per share ...

Core Insights - OraSure Technologies, Inc. has launched the HEMAcollect™ ● PROTEIN product aimed at enhancing proteomic research through improved sample collection and preservation [1][2] - The HEMAcollect™ ● PROTEIN is an evacuated blood collection tube designed to stabilize plasma proteins for up to seven days, addressing limitations of traditional blood collection methods [1][2] - The product is expected to provide operational and financial efficiencies for proteomic researchers, facilitating high-quality data generation [1] Product Features - The HEMAcollect™ ● PROTEIN BCT utilizes ProteoPrecision™ technology to minimize hemolysis and platelet activation, ensuring sample integrity [2] - It is compatible with various proteomic technologies, including mass spectrometry and immunoassays, making it versatile for different research applications [2] Company Overview - OraSure Technologies focuses on transforming healthcare through innovative diagnostic tests and sample management solutions, serving a wide range of customers including clinical laboratories and pharmaceutical companies [4] - DNA Genotek, a subsidiary of OraSure, specializes in developing products that optimize sample collection and performance for high-quality biological samples [5]

Conference call to be held on Wednesday, July 30, 2025, at 8:30 a.m. Eastern TimeYOKNEAM, Israel, July 10, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter 2025 before the Nasdaq market opens on Wednesday, July 30, 2025.InMode is currently finalizing its financial results for the second quarter of 2025. While complete financial information and operating data a ...

Group 1: Stock Performance - CRISPR Therapeutics AG shares increased by 9.6% to close at $60.08, with notable trading volume compared to typical sessions [1] - The stock has gained 27.7% over the past four weeks, indicating strong investor interest [1] Group 2: Pipeline Developments - The rise in CRISPR's stock price is attributed to positive sentiment regarding its pipeline, particularly the in vivo candidate CTX310 targeting ANGPTL3 for atherosclerotic heart disease [2] - Updated data from an early-stage study showed a single dose of CTX310 resulted in peak reductions of up to 82% in triglyceride levels and up to 86% in LDL levels, generating excitement for other pipeline candidates [2] Group 3: Financial Expectations - The company is expected to report a quarterly loss of $1.54 per share, reflecting a year-over-year change of -3.4%, while revenues are projected at $5.89 million, a significant increase of 1032.9% from the previous year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, suggesting that stock price movements may be influenced by trends in earnings estimate revisions [4] Group 4: Industry Context - CRISPR Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, where Wave Life Sciences also operates, closing the last trading session 10.8% higher at $7.7 [4] - Wave Life Sciences has seen a consensus EPS estimate change of -6.6% over the past month, indicating a potential decline in performance compared to the previous year [5]

1. 申报重点领域 北京市重点实验室的布局将紧密围绕北京国际科技创新中心建设，重点支持以下领域： 新一代信息技术（如人工智能、大数据、5G/6G通信等）； 智能制造与装备（如工业互联网、智能机器人、高端装备制造等）； 新材料（如高性能材料、纳米材料、新能源材料等）； 新能源（如清洁能源、储能技术、碳中和相关技术等）。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们 的推送。 7月9日， 北京市科学技术委员会、中关村科技园区管理委员会联合发布了《2025年北京市重 点实验室申报指南》（京科机发〔2025〕135号）， 正式启动本年度北京市重点实验室申报 工作 。2025年北京市重点实验室申报工作紧密围绕北京国际科技创新中心建设的重点任务， 聚焦本市重点产业方向和前沿科技领域。申报领域 涵盖新一代信息技术、 医药健康、智能制 造与装备、新材料、新能源、农业科技 、智慧城市等关键领域。 （ 文 末 附 申 报 案 例 ） 医药健康（如生物医药、医疗器械、精准医疗等）； 智能制造与装备作为核心方向之一，将重点关注工业自动化、智能检测、数字孪生、工业软件 等 ...

Company Overview - DaVita HealthCare (DVA) closed at $141.84, down 1.36% from the previous trading session, underperforming the S&P 500 which gained 0.61% [1] - Prior to this trading day, DVA shares had increased by 3.37%, outperforming the Medical sector's decline of 0.67% but lagging behind the S&P 500's rise of 3.85% [1] Financial Performance Forecast - DaVita is expected to report an EPS of $2.7, reflecting a 4.25% increase from the same quarter last year [2] - Revenue is forecasted to be $3.3 billion, indicating a 3.5% growth compared to the same quarter last year [2] - For the full year, analysts anticipate earnings of $10.76 per share and revenue of $13.48 billion, representing increases of 11.16% and 5.15% respectively from the previous year [3] Analyst Estimates and Market Sentiment - Recent modifications to analyst estimates for DaVita are important as they indicate changing near-term business trends, with positive revisions suggesting optimism about the business outlook [4] - The Zacks Rank system, which incorporates estimate changes, currently ranks DaVita as 3 (Hold), with the consensus EPS estimate remaining unchanged over the past month [6] Valuation Metrics - DaVita's Forward P/E ratio is 13.37, which is lower than the industry average Forward P/E of 18.96, indicating a valuation discount [7] - The company has a PEG ratio of 0.99, compared to the industry average PEG ratio of 1.8, suggesting that DVA is relatively undervalued based on its expected earnings growth [8] Industry Context - The Medical - Outpatient and Home Healthcare industry, which includes DaVita, has a Zacks Industry Rank of 39, placing it in the top 16% of over 250 industries [9]

Adma Biologics (ADMA) ended the recent trading session at $18.34, demonstrating a +2.98% change from the preceding day's closing price. The stock outpaced the S&P 500's daily gain of 0.61%. On the other hand, the Dow registered a gain of 0.49%, and the technology-centric Nasdaq increased by 0.95%. Coming into today, shares of the infectious disease drug developer had lost 14.62% in the past month. In that same time, the Medical sector lost 0.67%, while the S&P 500 gained 3.85%. Market participants will be c ...

Core Viewpoint - FONAR Corporation's Board of Directors has received a non-binding proposal from a Proposed Acquisition Group led by Timothy Damadian to acquire all outstanding shares of FONAR not currently owned by the group, with an anticipated premium of at least 10% over the average closing market price for the 90 trading days prior to July 1, 2025 [1][2]. Group 1: Proposal Details - The Proposed Acquisition Group currently owns approximately 5.01% of FONAR's outstanding stock [1]. - A special committee of independent directors has been established to review the proposal and determine the best course of action for the company and its shareholders [2]. Group 2: Company Background - FONAR, incorporated in 1978 and went public in 1981, is recognized as the inventor of MR Scanning and has a long history in the MRI industry [5]. - The company's flagship product is the FONAR UPRIGHT® Multi-Position™ MRI, which allows for imaging in various weight-bearing positions, providing advantages over traditional lie-down MRI scanners [6][8]. Group 3: Technological Innovations - FONAR is developing new technology to visualize and quantify cerebrospinal fluid dynamics, which could benefit patients with neck injuries [9]. - The company holds numerous patents related to its MRI technology, including those for full weight-bearing imaging [11].

Core Viewpoint - Haemonetics Corporation will release its first quarter fiscal year 2026 financial results on August 7, 2025, and will hold a conference call for discussion with investors and analysts [1][2]. Company Information - Haemonetics is a global medical technology company focused on enhancing healthcare quality, effectiveness, and efficiency through innovative solutions [3]. - The company offers a range of technologies for hospitals, plasma collection centers, and blood centers to improve patient outcomes and operational efficiency [3]. Investor Relations - The conference call will take place at 8:00 am ET on August 7, 2025, with access available via teleconference and a live webcast on the investor relations website [2]. - A replay of the conference call will be available for one year starting from August 7, 2025 [2][4].